The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Predicting response to naratuximab emtansine, an anti-CD37 antibody-drug conjugate (ADC), in combination with rituximab in diffuse large B-cell lymphoma (DLBCL), by analyzing the spatial arrangement of CD37 and CD20 positive cells using deep learning.
 
Anna Pokorska-Bocci
Employment - Debiopharm Group
Patents, Royalties, Other Intellectual Property - Debiopharm Group
 
Sandrine Micallef
Employment - Debiopharm Group; Roche
Stock and Other Ownership Interests - Roche
 
Mariola Dymkowska
Consulting or Advisory Role - arGEN-X BVBA; Aurealis; Cantargia AB; Debiopharm Group; MorphoSys
 
Yuval Gabay
Employment - Nucleai
Stock and Other Ownership Interests - Nucleai
 
Roman Gluskin
Employment - Nucleai
Stock and Other Ownership Interests - Nucleai
 
Avi Laniado
Employment - Nucleai
 
Efrat Dicker Sagy
Employment - Nucleai
 
Amit Bart
Employment - Nucleai
 
Tomer Dicker
Employment - Nucleai
 
Ifat Rotbein
Employment - Nucleai
Stock and Other Ownership Interests - Nucleai
 
Albert Achtenberg
Employment - Nucleai
Leadership - Nucleai
Stock and Other Ownership Interests - Nucleai
 
Ori Zelichov
Employment - Nucleai
Leadership - Nucleai
Stock and Other Ownership Interests - Nucleai
Patents, Royalties, Other Intellectual Property - Nucleai